HealthDay on MSN1d
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate Cancer
For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination r ...
MedPage Today6d
Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPC
Opens in a new tab or window SAN FRANCISCO -- The addition of radionuclide therapy with 177 Lu-PSMA-617 (Pluvicto) to enzalutamide (Xtandi) improved overall survival (OS) in patients with ...
Targeted Oncology7d
Darolutamide Shows Stronger Benefits in Non-Metastatic Prostate Cancer
Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...
Medscape6d
Talazoparib Combo Prolongs Survival in Metastatic Prostate Cancer
Adding talazoparib to enzalutamide led to a statistically significant and clinically meaningful improvement in overall survival in patients with metastatic castration-resistant prostate cancer ...
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA Pharma
If you purchased or acquired securities in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to ...
MedPage Today7d
Talazoparib-Enzalutamide Improves Survival in Metastatic CRPC
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration ...